Steven Waggoner

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

Krishnansu S. Tewari, Michael W. Sill, Richard T. Penson et al. · The Lancet · 2017 · 656 citations · Full text

Advanced Cervical Cancer, Cervical Cancer Management, Cervical Cancer +11

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma

Panagiotis A. Konstantinopoulos, Steven Waggoner, Gregory A. Vidal et al. · JAMA Oncology · 2019 · 533 citations · Full text

Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies

Arno J. Mundt, Anthony E. Lujan, Jacob Rotmensch et al. · International Journal of Radiation Oncology*Biology*Physics · 2002 · 467 citations

Adaptive Radiotherapy, Radiation Therapy, Medicine +5

Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study

Maurie Markman, John A. Blessing, Stephen C. Rubin et al. · Gynecologic Oncology · 2005 · 243 citations

Phase Ii Trial, Medicine, Cancer Management +8

Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study

Kian Behbakht, Michael W. Sill, Kathleen M. Darcy et al. · Gynecologic Oncology · 2011 · 203 citations · Full text

Phase Ii Trial, Medicine, Metronomic Therapy +9